Oct 2026· Annals of Surgical Oncology· 1 citation· 15 references
Medicine
TL;DR
Patients with resectable BTC with elevated CA19-9 or clinical lymph node positivity are at high risk of early recurrence and limited treatment feasibility after recurrence, and NAC may improve outcomes in this population by delaying recurrence.
BACKGROUND
Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated w...
T. Taira, Mitsuhito Sasaki, G. Igarashi et al.· International Journal of Cli...· 0 citations
Preoperative treatment is central to rectal cancer, but its benefit in elderly patients remains unclear. This study evaluated its impact on clinical outcomes in elderly patients undergoing surgery.
This cohort included 5,533 patients aged ≥65 years with newly diagnosed locally advanced rectal cancer (LARC) w...
Tung Lin, Te-Min Ke, Wan-Hsuan Chow et al.· Clinical Medicine Insights:...· 0 citations
BACKGROUND
Current National Comprehensive Cancer Network (NCCN) guidelines recommend omission of adjuvant therapy in esophageal cancer patients achieving pathological complete response (pCR) following neoadjuvant treatment. However, 20-40% of these patients experience disease recurrence, potentially indicative of resid...
Zi-An Zhang, Jun-Feng Liu, Jun-Hong Liu et al.· European Journal of Surgical...· 0 citations
Background: Disease recurrence is common after surgery for pleural mesothelioma (PM), and the evidence guiding post-recurrence management remains limited. Methods: We conducted a retrospective, single-center cohort study including patients with PM treated within a curative-intent multimodality treatment pathway includi...
O. Illini, H. Fabikan, Irene Berghammer et al.· Journal of Clinical Medicine· 0 citations
Abstract Background Perioperative chemotherapy is the standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients...
Aravind Sreeram, Celine Yeh, N. Toumbacaris et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.